{
    "name": "bromfenac ophthalmic",
    "comment": "Rx",
    "other_names": [
        "BromSite",
        "Prolensa"
    ],
    "classes": [
        "Ophthalmic NSAIDs"
    ],
    "source": "https://reference.medscape.com/drug/bromsite-prolensa-bromfenac-ophthalmic-343667",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women to inform any drug-associated risks",
            "Because of known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of this drug during late pregnancy should be avoided"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Treatment of pregnant rats and rabbits with oral bromfenac did not produce teratogenic effects at clinically relevant doses"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of bromfenac in human milk, effects on breastfed infant, or on milk production; however, systemic exposure to this drug from ocular administration is low",
            "Developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for bromfenac and any potential adverse effects on the breastfed child from bromfenac or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None listed by manufacturer"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Contains sodium sulfite which may cause allergic reactions in susceptible individuals",
                "Topical nonsteroidal anti-inflammatory drugs (NSAIDs), may slow or delay healing; topical corticosteroids are also known to slow or delay healing; concomitant use of topical NSAIDs and topical steroids may increase potential for healing problems",
                "Potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs; use caution when treating individuals who have previously exhibited sensitivities to these drugs",
                "Interferes with platelet aggregation; there have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery; recommended that the drug be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time",
                "Remove contact lenses before application, may reinsert 10 minutes after instilling drops",
                "Corneal adverse reactions may occur in patients with keratitis after continued use that may result in loss of vision; discontinue use in patients with evidence of corneal epithelial damage",
                "Use caution in patients with diabetes (may be at risk of corneal adverse effects that may result in loss of vision)",
                "Use caution in patients with complicated ocular surgeries, corneal denervation, repeat ocular surface disease, or corneal epithelial defects",
                "Use caution in patients with rheumatoid arthritis"
            ],
            "specific": [
                {
                    "type": "Keratitis and corneal reactions",
                    "description": [
                        "Use of topical NSAIDs may result in keratitis; in some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation",
                        "These events may be sight-threatening; patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including this drug, and should be closely monitored for corneal health",
                        "Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (eg, dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight-threatening",
                        "Topical NSAIDs should be used with caution in these patients; post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days postsurgery may increase patient risk for the occurrence and severity of corneal adverse events"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Abnormal sensation in eye",
            "percent": null
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": null
        },
        {
            "name": "Eye irriation",
            "percent": null
        },
        {
            "name": "burning",
            "percent": null
        },
        {
            "name": "stinging",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Eye pruritus",
            "percent": null
        },
        {
            "name": "Eye redness",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Iritis",
            "percent": null
        },
        {
            "name": "Corneal erosion",
            "percent": null
        }
    ]
}